John Libbey Eurotext

Hématologie

MENU

Leucémie lymphoïde chronique du sujet de plus de 80 ans : enfin des données prospectives sur les caractéristiques des patients et le traitement ! Volume 25, issue 1, Janvier-Février 2019

  • [1] Goede V., Fsicher K., Busch R. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2011;370:1101-1110.
  • [2] Burger J.A., Tedeschi A., Barr P.M. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-2437.
  • [3] Bairey O., Ruchlemer R., Rahimi-Levene N.C. Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. Ann Haematol. 2011;90:1123.
  • [4] Meunier G., Ysebaert L., Nguyen-Thi P.I. First line therapy for chronic lymphocytic leukemia in patients older than 79 years old is feasible and achieves good results. A FILO retrospective study. Hematol Oncol. 2017;35:671-678.
  • [5] Al Sawaf O., Bahlo J., Robrecht S. Outcome of patients aged 80 or older treated for chronic lymphocytic leukemia. Br J Haematol. 2018;183:727-773.